TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

Condition(s) studied

Study summary

This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.

Eligibility

Primary outcome measure(s)

• Overall Survival (OS) — Up to 24 months
  Overall survival (OS) is defined as the time from the initiation of atezolizumab treatment to the date of death from any cause.

Trial sites (25)

More Antalya Training and Research Hospital trials in Turkey